000126644 001__ 126644
000126644 005__ 20240228140838.0
000126644 0247_ $$2doi$$a10.1186/s12885-015-1886-5
000126644 0247_ $$2pmid$$apmid:26547188
000126644 0247_ $$2pmc$$apmc:PMC4637144
000126644 0247_ $$2altmetric$$aaltmetric:4736798
000126644 037__ $$aDKFZ-2017-02672
000126644 041__ $$aeng
000126644 082__ $$a610
000126644 1001_ $$aHabl, Gregor$$b0
000126644 245__ $$aHelical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.
000126644 260__ $$aLondon$$bBioMed Central$$c2015
000126644 3367_ $$2DRIVER$$aarticle
000126644 3367_ $$2DataCite$$aOutput Types/Journal article
000126644 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522151875_11125
000126644 3367_ $$2BibTeX$$aARTICLE
000126644 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126644 3367_ $$00$$2EndNote$$aJournal Article
000126644 520__ $$aDefinitive, percutaneous irradiation of the prostate and the pelvic lymph nodes in high-risk prostate cancer is the alternative to prostatectomy plus lymphadenectomy. To date, the role of whole pelvis radiotherapy (WPRT) has not been clarified especially taking into consideration the benefits of high conformal IMRT (intensity modulated radiotherapy) of complex-shaped target volumes.From 2009 to 2012, 40 patients of high-risk prostate cancer with an increased risk of microscopic lymph node involvement were enrolled into this prospective phase II trial. Patients received at least two months of antihormonal treatment (AT) before radiotherapy continuing for at least 2 years. Helical IMRT (tomotherapy) of the pelvic lymph nodes (51.0 Gy) with a simultaneous integrated, moderate hypofractionated boost (single dose of 2.25 Gy) to the prostate (76.5 Gy) was performed in 34 fractions. PSA levels, prostate-related symptoms and quality of life were assessed at regular intervals for 24 months.Of the 40 patients enrolled, 38 finished the treatment as planned. Overall acute toxicity rates were low and no acute grade 3 or 4 gastrointestinal (GI) and genitourinary (GU) toxicity occurred. 21.6% of patients experienced acute grade 2 but no late grade ≥ 2 GI toxicity. Regarding GU side effects, results showed 48.6% acute grade 2 and 6.4% late grade 2 toxicity. After a median observation time of 23.4 months the PLATIN 1 trial can be considered as sufficiently safe meeting the prospectively defined aims of the trial. With 34/37 patients free of a PSA recurrence it shows promising efficacy.Tomotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate can be performed safely and without excessive toxicity. The combined irradiation of both prostate and pelvic lymph nodes seems to be as well tolerated as the irradiation of the prostate alone.Trial Numbers: ARO 2009-05, ClinicalTrials.gov: NCT01903408.
000126644 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000126644 588__ $$aDataset connected to CrossRef, PubMed,
000126644 7001_ $$aKatayama, Sonja$$b1
000126644 7001_ $$aUhl, Matthias$$b2
000126644 7001_ $$aKessel, Kerstin A$$b3
000126644 7001_ $$0P:(DE-He78)621efe295db6fdfa7f9f95011a5ea943$$aEdler, Lutz$$b4$$udkfz
000126644 7001_ $$0P:(DE-HGF)0$$aDebus, Juergen$$b5
000126644 7001_ $$aHerfarth, Klaus$$b6
000126644 7001_ $$0P:(DE-He78)75d45845a04db67c5a88db1086046ef1$$aSterzing, Florian$$b7$$eLast author$$udkfz
000126644 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-015-1886-5$$gVol. 15, no. 1, p. 868$$n1$$p868$$tBMC cancer$$v15$$x1471-2407$$y2015
000126644 909CO $$ooai:inrepo02.dkfz.de:126644$$pVDB
000126644 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)621efe295db6fdfa7f9f95011a5ea943$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000126644 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000126644 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)75d45845a04db67c5a88db1086046ef1$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000126644 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000126644 9141_ $$y2015
000126644 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2015
000126644 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126644 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126644 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126644 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000126644 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000126644 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000126644 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000126644 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000126644 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126644 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126644 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126644 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000126644 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000126644 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000126644 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x1
000126644 980__ $$ajournal
000126644 980__ $$aVDB
000126644 980__ $$aI:(DE-He78)C060-20160331
000126644 980__ $$aI:(DE-He78)E050-20160331
000126644 980__ $$aUNRESTRICTED